Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
IPO Year: 2010
Exchange: NASDAQ
Website: codexis.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/19/2024 | Buy → Hold | The Benchmark Company | |
| 6/3/2024 | $5.00 | Buy | Jefferies |
| 5/30/2024 | $11.00 | Overweight | Cantor Fitzgerald |
| 2/29/2024 | Hold → Buy | The Benchmark Company | |
| 11/7/2023 | Buy → Hold | The Benchmark Company | |
| 8/7/2023 | $21.00 → $4.00 | Outperform → Market Perform | TD Cowen |
| 5/9/2023 | Buy → Neutral | H.C. Wainwright | |
| 3/31/2022 | $35.00 | Overweight | Piper Sandler |
| 3/2/2022 | Outperform | Cowen | |
| 11/5/2021 | $33.00 → $38.00 | Buy | HC Wainwright & Co. |
Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes Three CDMO presentations to feature data on performance of Codexis double-stranded RNA ligases Management will host a conference call at 8 am Eastern Time on Thursday, May 22 to discuss data REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will host two data presentations and one poster at the upcoming TIDES USA annual meeting, being held May 19-22, 2025, in San Diego, California. Codexis' presentations wil
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the first quarter of 2025 on Wednesday, May 14, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (inter
REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that Byron Dorgan will retire from the Company's Board of Directors when his current term ends at the 2025 Annual Meeting of Stockholders. Mr. Dorgan joined the Board in 2011, served as Chairman from 2021 through 2024, and currently serves as the Chair of the Nominating and Corporate Governance Committee. He will remain a consultant to Codexis for one year following his departure from the Board. "On behalf of the entire Board of Directors, I want to express our appreciation for Byron's valuabl
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company's Board of Directors. "I am thrilled to welcome Cindy to our Board," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. "She has been at the forefront of innovation across multiple therapeutic modalities and brings a wealth of knowledge about the CDMO landscape. I look forward to her valuable guidance as we continue expanding the commercial footprint of our ECO Synthesis toolbox." Ms. Collins added,
Represents first project to enter the ECO Synthesis™ Innovation Lab Core enzymes for ECO Synthesis™ technology have transitioned from research into development and scale-up as the first step in securing the raw materials supply chain REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced its first revenue-generating contract to manufacture siRNA material in its ECO Synthesis™ Innovation Lab. Codexis has also successfully completed development of the first generation of its core ECO Synthesis™ enzymes, having met the pre-specified criteria to sup
REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 10,000 shares of Codexis common stock and (ii) 5,000 restricted stock units (RSUs) as inducement awards under the Company's 2024 Inducement Plan. The stock options have an exercise price equal to the closing price per share of Codexis' common stock as reported by Nasd
Total revenue of $59.3 million for the fiscal year ended December 31, 2024 Expect double digit growth for total revenue in 2025 2025 to demonstrate acceleration of commercial growth through double-stranded RNA ligase and GLP-grade siRNA material; expect to secure GMP scale-up partner REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. "Throughout 2024, we continued to execute our strategy to advance the ECO Synthesis™ platform, a
REDWOOD CITY, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the TD Cowen 45th Annual Health Care Conference, being held March 3-5, 2025, in Boston, Massachusetts. Management will participate in a fireside chat on Tuesday, March 4, 2025, at 1:10 pm ET. A live webcast of the event will be available in the Investor Relations section of the Company's website, https://ir.codexis.com. A replay will be archived for 90 days following the event. About Codexis Codexis is a leading provider of enzymatic solutions for efficient and scalabl
REDWOOD CITY, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 39,000 shares of Codexis common stock and (ii) 27,500 restricted stock units (RSUs) as inducement awards under the Company's 2024 Inducement Plan. The stock options have an exercise price equal to the closing price per share of Codexis' common stock as reported by Nas
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the fourth quarter and fiscal year 2024 on Thursday, February 27, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 20
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
3 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
4 - CODEXIS, INC. (0001200375) (Issuer)
SC 13G - CODEXIS, INC. (0001200375) (Subject)
SC 13G/A - CODEXIS, INC. (0001200375) (Subject)
SC 13G - CODEXIS, INC. (0001200375) (Subject)
SC 13G/A - CODEXIS, INC. (0001200375) (Subject)
SC 13G/A - CODEXIS, INC. (0001200375) (Subject)
SC 13G - CODEXIS, INC. (0001200375) (Subject)
SC 13G/A - CODEXIS, INC. (0001200375) (Subject)
SC 13G/A - CODEXIS, INC. (0001200375) (Subject)
SC 13G/A - CODEXIS, INC. (0001200375) (Subject)
SC 13G/A - CODEXIS, INC. (0001200375) (Subject)
DEFA14A - CODEXIS, INC. (0001200375) (Filer)
DEF 14A - CODEXIS, INC. (0001200375) (Filer)
8-K - CODEXIS, INC. (0001200375) (Filer)
8-K - CODEXIS, INC. (0001200375) (Filer)
10-K - CODEXIS, INC. (0001200375) (Filer)
8-K - CODEXIS, INC. (0001200375) (Filer)
8-K - CODEXIS, INC. (0001200375) (Filer)
8-K - CODEXIS, INC. (0001200375) (Filer)
10-Q - CODEXIS, INC. (0001200375) (Filer)
8-K - CODEXIS, INC. (0001200375) (Filer)
Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes Three CDMO presentations to feature data on performance of Codexis double-stranded RNA ligases Management will host a conference call at 8 am Eastern Time on Thursday, May 22 to discuss data REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will host two data presentations and one poster at the upcoming TIDES USA annual meeting, being held May 19-22, 2025, in San Diego, California. Codexis' presentations wil
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the first quarter of 2025 on Wednesday, May 14, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (inter
Total revenue of $59.3 million for the fiscal year ended December 31, 2024 Expect double digit growth for total revenue in 2025 2025 to demonstrate acceleration of commercial growth through double-stranded RNA ligase and GLP-grade siRNA material; expect to secure GMP scale-up partner REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. "Throughout 2024, we continued to execute our strategy to advance the ECO Synthesis™ platform, a
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the fourth quarter and fiscal year 2024 on Thursday, February 27, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 20
—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset— —Joint poster with Bachem demonstrates superiority of Company's double-stranded RNA ligases compared to wild-type enzymes— —Management to host conference call today at 4:30 pm EST to discuss data— REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from three presentations at the TIDES Europe annual meeting being held November 12-14, 2024, in Hamburg, Germany. The data demonstrate the Company's rapid advancement of its Enzyme Catalyzed Oligon
—Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type enzymes— —Management to host conference call on Thursday, November 14 to discuss data— REDWOOD CITY, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will demonstrate real-world application of its enzymatic synthesis platform via three presentations at the upcoming TIDES Europe annual meeting, being held November 12-14, 2024, in Hamburg, Germany.
Quarter Highlights Include Key Additions to Management Team and Extension of Cash Runway into 2027 with $31M Raise via ATM Facility Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue Growth of at Least 10% vs. FY2023 Excluding Enzyme Sales Related to PAXLOVID™ REDWOOD CITY, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. "Codexis had a strong third quarter, in which we surpassed product revenue goals, welcomed two new, high
REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on Thursday, October 31, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (int
Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue Growth of at Least 10% vs. FY2023 Excluding Enzyme Sales Related to PAXLOVID™ Anticipate Entering First Technical Collaboration for ECO Synthesis™ Manufacturing Platform by End of Year REDWOOD CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. "We're pleased that our second quarter revenues are exactly in-line with our expectations. As a result, we are reiterating our 2024 financial guidance and look forward to a strong second half
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for at least 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be
The Benchmark Company downgraded Codexis from Buy to Hold
Jefferies resumed coverage of Codexis with a rating of Buy and set a new price target of $5.00
Cantor Fitzgerald initiated coverage of Codexis with a rating of Overweight and set a new price target of $11.00
The Benchmark Company upgraded Codexis from Hold to Buy
The Benchmark Company downgraded Codexis from Buy to Hold
TD Cowen downgraded Codexis from Outperform to Market Perform and set a new price target of $4.00 from $21.00 previously
H.C. Wainwright downgraded Codexis from Buy to Neutral
Piper Sandler resumed coverage of Codexis with a rating of Overweight and set a new price target of $35.00
Cowen resumed coverage of Codexis with a rating of Outperform
HC Wainwright & Co. reiterated coverage of Codexis with a rating of Buy and set a new price target of $38.00 from $33.00 previously
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company's Board of Directors. "I am thrilled to welcome Cindy to our Board," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. "She has been at the forefront of innovation across multiple therapeutic modalities and brings a wealth of knowledge about the CDMO landscape. I look forward to her valuable guidance as we continue expanding the commercial footprint of our ECO Synthesis toolbox." Ms. Collins added,
REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Arthur Levin, PhD, to the Company's Strategic Advisory Board (SAB). Dr. Levin is a founding member of Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called antibody oligonucleotide conjugates, and currently serves on its Board of Directors. He brings three decades of experience developing oligonucleotides to Codexis as it continues to onboard customers for its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufact
REDWOOD CITY, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Christos Richards to the Company's Board of Directors. "I am delighted to welcome Christos to our Board. His broad and deep knowledge and understanding of the life sciences industry will be invaluable as we continue the transformation of Codexis," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. Mr. Richards added, "As a longstanding partner to the biopharmaceutical industry, I'm well aware of the potential of Codexis' proprietary technologies
REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Raymond De Vré, PhD, to the Company's Board of Directors. "We are thrilled to have Raymond join the Codexis Board of Directors. He will be an invaluable resource to Codexis," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. "Raymond brings a deep understanding of the commercial and regulatory landscape as well as direct experience in oligonucleotide manufacturing." "Codexis and its ECO Synthesis platform represent the next generation of innovat
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog
Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of growth REDWOOD CITY, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an increase in its cash reserves through capital raises totaling $31 million via the Company's existing at-the-market facility during the quarter ended September 30, 2024. These funds are in addition to the $73.2 million in cash, cash equivalents and investments on hand as of June 30, 2024. In
REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company's Strategic Advisory Board (SAB). Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications. Her deep biotechnology experience includes leadership roles across fermentation-based commercial manufacturing, process development, plant operations and global supply chain management. "We are honored to have Carole join Codexis as the newest member of our Strategic Advisory Board," sa
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to the Company's Strategic Advisory Board (SAB), joining John Maraganore, PhD, the founder and former Chief Executive Officer of Alnylam Pharmaceuticals. This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company's strategic direction, providing critical insights to inform the continued development of Codexis' ECO Synthesis™ manufacturing platform. "We are thrilled to have Masad and Jim lend their decades of experience
REDWOOD CITY, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of Sri Ryali as Chief Financial Officer effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in life sciences to Codexis. In this role, Mr. Ryali will lead all aspects of the Company's financial operations and will report directly to Dr. Stephen Dilly, President and Chief Executive Officer of Codexis. "I am excited to announce the addition of Sri to Codexis as we continue to build a top executive leadership team with the strategic acumen, operational experience and commercial mindset to deliver on our pr
REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors. "Stewart's deep expertise in gene therapy and demonstrated track record of executive leadership within the biopharmaceutical industry make her a compelling addition as we seek to continue to strengthen the diversity of our Board with a breadth of professional experience, educational background, and viewpoints," said Byron Dorgan, Chair of the Board of Codexis. "In particular, her experience advising publicly traded pharmaceutical and genomic therapy companies will be valuable as we continu